These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 3044983)

  • 41. Effect of carrier selection on immunogenicity of protein conjugate vaccines against Plasmodium falciparum circumsporozoites.
    Que JU; Cryz SJ; Ballou R; Fürer E; Gross M; Young J; Wasserman GF; Loomis LA; Sadoff JC
    Infect Immun; 1988 Oct; 56(10):2645-9. PubMed ID: 3047062
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced antibody response to the repetitive sequence of the Plasmodium falciparum circumsporozoite protein in mice infected with Plasmodium yoelii blood forms.
    Grillot D; Pessi A; Verdini AS; Lambert PH; Del Giudice G
    Med Microbiol Immunol; 1990; 179(5):237-44. PubMed ID: 2082157
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sporozoite immunity and vaccine development.
    Hockmeyer WT; Ballou WR
    Prog Allergy; 1988; 41():1-14. PubMed ID: 3043419
    [No Abstract]   [Full Text] [Related]  

  • 44. Synthetic peptide vaccine confers protection against murine malaria.
    Zavala F; Tam JP; Barr PJ; Romero PJ; Ley V; Nussenzweig RS; Nussenzweig V
    J Exp Med; 1987 Nov; 166(5):1591-6. PubMed ID: 3316473
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates.
    Fraser CC; Altreuter DH; Ilyinskii P; Pittet L; LaMothe RA; Keegan M; Johnston L; Kishimoto TK
    Vaccine; 2014 May; 32(24):2896-903. PubMed ID: 24583006
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A promising model of primary human immunization in human-scid mouse.
    Bombil F; Kints JP; Scheiff JM; Bazin H; Latinne D
    Immunobiology; 1996 Aug; 195(3):360-75. PubMed ID: 8877409
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antisporozoite vaccine for malaria: experimental basis and current status.
    Nussenzweig RS; Nussenzweig V
    Rev Infect Dis; 1989; 11 Suppl 3():S579-85. PubMed ID: 2669101
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Plasmodium falciparum malaria vaccine candidate which contains epitopes from the circumsporozoite protein and a blood stage antigen, 5.1.
    Caspers P; Etlinger H; Matile H; Pink JR; Stüber D; Takács B
    Mol Biochem Parasitol; 1991 Aug; 47(2):143-50. PubMed ID: 1719416
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Carrier-induced suppression of the antibody response to a 'self' hapten.
    Sad S; Gupta HM; Talwar GP; Raghupathy R
    Immunology; 1991 Oct; 74(2):223-7. PubMed ID: 1748470
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Construction of immunogens for synthetic malaria vaccines.
    Lise D; Dubeaux C; Tello D; Mazier D; Jolivet M; Schlesinger DH; Audibert F; Chedid L
    Biochem Biophys Res Commun; 1988 May; 153(1):31-8. PubMed ID: 3288205
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of priming with carrier on response to conjugate vaccine.
    Di John D; Wasserman SS; Torres JR; Cortesia MJ; Murillo J; Losonsky GA; Herrington DA; Stürcher D; Levine MM
    Lancet; 1989 Dec; 2(8677):1415-8. PubMed ID: 2480499
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine.
    Good MF; Berzofsky JA; Maloy WL; Hayashi Y; Fujii N; Hockmeyer WT; Miller LH
    J Exp Med; 1986 Aug; 164(2):655-60. PubMed ID: 2425037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Successful primate immunization with peptides conjugated to purified protein derivative or mycobacterial heat shock proteins in the absence of adjuvants.
    Perraut R; Lussow AR; Gavoille S; Garraud O; Matile H; Tougne C; van Embden J; van der Zee R; Lambert PH; Gysin J
    Clin Exp Immunol; 1993 Sep; 93(3):382-6. PubMed ID: 8370164
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preparation of proteosome-based vaccines. Correlation of immunogenicity with physical characteristics.
    Ruegg CL; Jaffe RI; Köster B; Sadoff JC; Zollinger WD; Lowell GH; Strand M
    J Immunol Methods; 1990 Dec; 135(1-2):101-9. PubMed ID: 2125617
    [TBL] [Abstract][Full Text] [Related]  

  • 55. 1H-NMR studies of synthetic polypeptide models of Plasmodium falciparum circumsporozoite protein tandemly repeated sequence.
    Esposito G; Pessi A; Verdini AS
    Biopolymers; 1989 Jan; 28(1):225-46. PubMed ID: 2655733
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Immunogenicity of Plasmodium falciparum circumsporozoite protein multiple antigen peptide vaccine formulated with different adjuvants.
    Le TP; Church LW; Corradin G; Hunter RL; Charoenvit Y; Wang R; de la Vega P; Sacci J; Ballou WR; Kolodny N; Kitov S; Glenn GM; Richards RL; Alving CR; Hoffman SL
    Vaccine; 1998; 16(2-3):305-12. PubMed ID: 9607047
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Can malaria-associated polyclonal B-lymphocyte activation interfere with the development of anti-sporozoite specific immunity?
    Daniel-Ribeiro C; de Oliveira-Ferreira J; Banic DM; Galvão-Castro B
    Trans R Soc Trop Med Hyg; 1989; 83(3):289-92. PubMed ID: 2694457
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cyclic OmpC peptidic epitope conjugated to tetanus toxoid as a potential vaccine candidate against shigellosis.
    Jarząb A; Witkowska D; Ziomek E; Setner B; Czajkowska A; Dorot M; Szewczuk Z; Gamian A
    Vaccine; 2018 Jul; 36(31):4641-4649. PubMed ID: 29960802
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Estimate of Plasmodium falciparum sporozoite content of Anopheles stephensi used to challenge human volunteers.
    Davis JR; Murphy JR; Clyde DF; Baqar S; Cochrane AH; Zavala F; Nussenzweig RS
    Am J Trop Med Hyg; 1989 Feb; 40(2):128-30. PubMed ID: 2645802
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Evidence for CD4+ T cell responses common to Plasmodium falciparum and recall antigens.
    Goodier MR; Targett GA
    Int Immunol; 1997 Dec; 9(12):1857-65. PubMed ID: 9466313
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.